Novavax Inc insider trading
Every open-market purchase and sale by Novavax Inc's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Novavax Inc’s insiders pay?
From April 13, 2011 to January 2, 2025, 17 insiders reported 63 open-market purchases and 52 sales not made under a pre-set plan in Novavax Inc. Twelve months after each purchase was reported, the shares were +5.8% against the S&P 500 on average (median −32.6%), over 14 purchases with a full year of prices; 36% beat the index. After sales, the shares moved +85.9% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 5, 2014 into $13,667 by November 2, 2026, +2.5% a year. It held shares 40% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $23,710 (+7.0% a year), and held throughout $53,436 (+14.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Glenn Gregory M | President, R&D | 9 | −43.7% (1) | 0% | 8 | +340.1% (5) | March 14, 2023 |
| Young James F | Director | 5 | +311.2% (1) | 100% | 10 | −58.0% (8) | January 2, 2025 |
| Evans Gary C | Director | 0 | — | — | 11 | −35.4% (9) | June 3, 2021 |
| Erck Stanley C | President and CEO | 9 | −2.1% (2) | 50% | 1 | −93.5% (1) | May 15, 2018 |
| Trizzino John | EVP, CBO and CFO | 8 | −37.6% (2) | 0% | 2 | +804.0% (2) | August 20, 2020 |
| Modi Rajiv I. | Director | 0 | — | — | 8 | −17.1% (6) | June 18, 2015 |
| Phillips Barclay A | SVP, Chief Financial Officer | 7 | −2.1% (2) | 50% | 1 | −49.1% (1) | May 11, 2017 |
| Douglas Richard | Director | 7 | — | — | 0 | — | May 12, 2017 |
| Hahn Timothy Jon | SVP, Manufacturing | 7 | −2.1% (2) | 50% | 0 | — | February 3, 2015 |
| Herrmann John A III | EVP, Chief Legal Officer | 2 | −32.6% (1) | 0% | 4 | +396.5% (4) | August 20, 2020 |
| Mcmanus Michael A Jr | Director | 2 | — | — | 3 | −13.7% (2) | March 23, 2021 |
| King Rachel K. | Director | 2 | −60.7% (1) | 0% | 1 | −31.8% (1) | January 2, 2025 |
| Wilson Russell P | SVP, Business Development | 3 | −2.1% (2) | 50% | 0 | — | February 3, 2015 |
| Dubovsky Filip | President, R&D | 0 | — | — | 2 | −63.4% (2) | June 20, 2024 |
| Boudreaux Gail | Director | 1 | — | — | 0 | — | September 21, 2016 |
| Driscoll Frederick W | VP, CFO & Treasurer | 1 | — | — | 0 | — | August 11, 2011 |
| Mott David M | Director | 0 | — | — | 1 | −74.7% (1) | September 24, 2021 |
When several insiders traded Novavax Inc
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Novavax Inc in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged −22.9% against the index. After 4 selling crowds, +46.0%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2021 | 3 selling | +8.7% | +1.9% | −76.0% |
| August 31, 2020 | 5 selling | +22.4% | +56.3% | +85.0% |
| September 30, 2019 | 3 selling | −29.0% | +182.7% | +2036.2% |
| March 31, 2016 | 2 buying | +37.9% | −63.9% | −92.9% |
| August 31, 2015 | 5 selling | −26.6% | −57.0% | −48.1% |
| February 27, 2015 | 6 buying | −2.3% | +31.5% | −46.1% |
| February 28, 2014 | 4 buying | −30.3% | −36.2% | +23.4% |